Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Bispecific anti-CD20 and anti-CD19 CAR T Cell Therapy Shows Efficacy in B Cell M...
Nirav N. Shah, MD, an associate professor at the Medical College of Wisconsin, discusses bispecific anti-CD20 and anti-CD19 chimeric antigen receptor (CAR) T cells in a phase 1 dose escalation and expansion trial (NCT03019055) for relapsed B cell malignancies.
Unanswered Questions Remain in DLBCL With Use of CAR T-Cell Therapies
In an interview with Targeted Oncology, Caron Jacobson, MD, discussed the data supporting use of CAR T-cell therapy as treatment of patients with diffuse large B-cell lymphoma and some of the remaining questions in this space that need to be addressed as these cellular therapies advanced forward in the field.
Off-the-Shelf CAR T-Cell Products Show Potential in DLBCL
Loretta J. Nastoupil, MD, an assistant professor in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center, discusses the use of off-the-shelf chimeric antigen receptor (CAR) T-cell products for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) and other cancers.
Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large...
Cancer-associated venous thromboembolism (VTE) constitutes a major cause of morbidity and mortality in patients with hematologic malignancies.1 VTE can occur after chimeric antigen receptor (CAR) T-cell therapy, whereas coagulopathy in the form of low fibrinogen and bleeding can be complications of cytokine release syndrome (CRS).
Infection during the first year in patients treated with CD19 CAR T cells for di...
CD19-targeted chimeric antigen receptor (CAR) T cell therapy is an effective treatment for diffuse large B cell lymphoma (DLBCL).